Gilat Reports Third Quarter 2025 Results

(NASDAQ:GILT),(TASE:GILT.TA), Revenues Increased by 58%, GAAP Operating Income Rose to $7.5 Million, Adjusted EBITDA Grew to $15.6 Million Raising Midpoint of 2025 Revenue and Adjusted EBITDA Guidance PETAH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today […]

Gilat Reports Third Quarter 2025 Results

Gilat Reports Third Quarter 2025 Results GlobeNewswire November 12, 2025 Revenues Increased by 58%, GAAP Operating Income Rose to $7.5 Million, Adjusted EBITDA Grew to $15.6 Million Raising Midpoint of 2025 Revenue and Adjusted EBITDA Guidance PETAH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide

Awardco Unveils New Era of Innovation in Employee Engagement at RCGNZ Summit 2025

Announced at RCGNZ Summit 2025, Awardco Engage™ and a new native mobile app experience unite recognition, feedback, and action to set a new standard for employee recognition and engagement. Awardco, the leading employee recognition and rewards platform, today announced Awardco Engage™, an all-in-one employee listening and insights tool that empowers every voice, captures meaningful feedback,

Charlotte’s Web Reports Q3 2025 Results

Healthcare Focus, Product Innovation, and Cost Improvements (TSX: CWEB) (OTC: CWBHF), Charlotte's Web Holdings, Inc. (“Charlotte's Web” or the “Company”), a botanical wellness innovation companyand the market leader in cannabidiol (CBD) hemp extract wellness products, today announced results for the quarter ended September 30, 2025. All amounts are expressed in U.S. dollars. https://mma.prnewswire.com/media/2820559/Charlotte_s_Web_Holdings__Inc__Charlotte_s_Web_Reports_Q3_2025_R.jpg “Q3 2025

Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer

DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins from Fortrea, one of the world's leading contract research organizations (CROs), where he held senior leadership roles driving growth strategies

MONSTER ENERGY UNLEASHES ULTRA WILD PASSION

A refreshing passionfruit energy boost with zero sugar and full Monster attitude. Monster Energy is bringing the heat with the newest addition to its fan-favorite Monster Energy Ultra lineup: Ultra Wild Passion, a bold, vibrant and refreshingly light passionfruit flavor that delivers energy with zero sugar and all the attitude. https://mma.prnewswire.com/media/2820661/Monster_Ultra_Wild_Passion.jpg Ultra Wild Passion pairs

Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer

Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer Firm to target small to medium-sized biotech and pharma companies GlobeNewswire November 12, 2025 DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

(NASDAQ:UNCY), – Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end – Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

(NASDAQ:ZBIO), – Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 – – Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) – – Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor

Buc-ee’s Ranked America’s Top Quick Service Restaurant, Edging Out Kwik Trip and In-N-Out, dunnhumby Reports

Quick service restaurants with the strongest customer value propositions grew six times faster than most competitors dunnhumby, a global leader in customer data science, has named Buc-ee's as the top ranked U.S. quick service restaurant (QSR) in the Retailer Preference Index (RPI) QSR Edition. The RPI is a nationwide brand equity study that examines the

Scroll to Top